- Policy
- Including SKYCovione, 6 types of COVID-19 vaccines
- by Lee, Jeong-Hwan Sep 6, 2022 05:51am
- With the seventh outbreak of COVID-19 expected this winter, the type of COVID-19 vaccine and the age of vaccination are expected to expand ahead of the winter vaccination. Following the previously licensed Pfizer, Moderna, and Janssen vaccines, domestic SK Bioscience vaccines have been approved, and additional vaccines for omicron mutation
- Company
- Prevenar 13 set to make ₩40B this year
- by Nho, Byung Chul Sep 5, 2022 05:55am
- Pfizer’s Prevenar 13 was found to be maintaining its overwhelming 70% share in the pneumococcal vaccine market. According to its distribution & shipment performance data, sales of Prevenar 13 in 1H this year reached &8361;19.4 billion, and its annual sales are expected to exceed that of the &8361;38.1 made last year. In terms of
- Company
- What are the chances of Dovprela's successful benefits?
- by Eo, Yun-Ho Sep 5, 2022 05:55am
- Attention is focusing on whether the new tuberculosis drug Dovprela, which appeared in 50 years, can be listed on the insurance benefit list. According to related industries, Viatris Korea's Dovprela passed the HIRA Pharmaceutical Benefit Evaluation Committee on the 1st. Dovprela, which was approved in Korea in October last year after U.S.
- Policy
- Drugs granted conditional approv to report clinical progress
- by Lee, Hye-Kyung Sep 5, 2022 05:55am
- Treatments for life-threatening serious and rare diseases are being granted conditional approval from July 21st this year. However, to inform the public of the conditions, items for which data on confirmatory clinical trials were not submitted should be specified in the label’s indication, and the clinical trial status of the subject drugs
- Company
- It has been a year since the release of Leclaza
- by Chon, Seung-Hyun Sep 5, 2022 05:55am
- Korea's first new anti-cancer drug is expected to generate 10 billion won in annual sales. Leclaza, a new anti-cancer drug developed by Yuhan Corporation, surpassed 10 billion won in cumulative sales within a year of its release in Korea. It showed a smooth move in the early stages of its release and predicted that it would surpass 10 billion
- Policy
- MFDS has launched permission review for Pfizer Comirnaty 2
- by Kim, Jung-Ju Sep 5, 2022 05:55am
- Pfizer's COVID-19 2-valent vaccine Comirnaty2 0.1mg/mL permission review has begun. The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced that Pfizer Korea has applied for permission today (29th) to import 0.1mg/mL of Comirnati 2, an mRNA-type bivalent vaccine that expresses the initial COVID-19 virus and mutant virus (Omi
- Company
- Vyndamax is finally a step towards benefits
- by Eo, Yun-Ho Sep 2, 2022 06:03am
- Transthyretin cardiomyopathy new drug Vyndamax has finally made progress. According to related industries, Vyndamax, a treatment for ATTR-CM (ATTR amyloidosis with cardiomyopathy) caused by Transthyretin amyloidosis in Pfizer, recently passed the HIRA Pharmaceutical Benefit Standards Subcommittee. This is the result of his fourth attempt. As
- Policy
- Will Migraine drug Ajovy be reimbursed following Emgality?
- by Lee, Tak-Sun Sep 2, 2022 06:03am
- With the new migraine drug Emgality (galcanezumab, Lilly) being applied reimbursement in Korea starting this month, a green light has been given to Teva-Handok’s new migraine drug as well. The new drug has passed the reimbursement adequacy assessment of the Health Insurance Review and Assessment Service, after which the company will be enter
- Policy
- The MFDS reviews Pfizer's vaccine permission for infants
- by Lee, Hye-Kyung Sep 2, 2022 06:03am
- The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced on the 1st that Pfizer Korea has begun reviewing the item as it applied for permission for imported items of the early COVID-19 vaccine for infants (6 months to 4 years old). The efficacy of "Comirnati 0.1mg/mL (for ages 6 months to 4 years)" applied this time is "Preve
- Company
- Q2 sales of Nexavar and Lenvima both sluggish
- by Kim, Jin-Gu Sep 2, 2022 06:03am
- Sales of all major liver cancer treatments are on the decline. Sales of Nexavar (sorafenib), which had dominated the first-line treatment market for liver cancer for over a decade, is on a continuous decline since the entry of its generics, and sales of Nexavar’s main competitor Lenvima have also been shown to be slowing down recently
